Jaewoo Choi

Jaewoo Choi

Auto-generated profile, based on publicly available information

Jaewoo Choi

Graduate School of Medical Science, Brain Korea 21 Project, Institute of Genetic Science, Department of Biochemistry and Molecular Biology, Yonsei University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2024 in Cancer Cell
Verified
Journal Article
Closed access
ABArnold Bolomsky
Arnold Bolomsky
MCMichele Ceribelli
Michele Ceribelli
SSSebastian Scheich
Sebastian Scheich
KRKristina Rinaldi
Kristina Rinaldi
DHDa Wei Huang
Da Wei Huang
RYRyan M. Young
Ryan M. Young

25 April 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SCSean R. Corcoran
Sean R. Corcoran
JPJames D. Phelan
James D. Phelan
JCJaewoo Choi
Jaewoo Choi
GSGalina Shevchenko
Galina Shevchenko
RFRachel E. Fenner
Rachel E. Fenner
LSLouis M. Staudt
Louis M. Staudt
Polatuzumab vedotin (Pola-V) is an antibody–drug conjugate directed to the CD79B subunit of the B-cell receptor (BCR). When combined with conventional immunochemotherapy, Pola-V improves outcomes in diffuse large B-cell lymphoma (DLBCL). To identify determinants of Pola-V sensitivity, we used CRISPR-Cas9 screening for genes that modulated Pola-V toxicity for lymphomas or the surface expression of its target, CD79B. Our results reveal the striking impact of CD79B glycosylation on Pola-V epitope availability on the lymphoma cell surface and on Pola-V toxicity. Genetic, pharmacological, and enzymatic approaches that remove sialic acid from N-linked glycans enhanced lymphoma killing by Pola-V. Pola-V toxicity was also modulated by KLHL6, an E3 ubiquitin ligase that is recurrently inactivated in germinal center derived lymphomas. We reveal how KLHL6 targets CD79B for degradation in normal and malignant germinal center B cells, thereby determining expression of the surface BCR complex. Our findings suggest precision medicine strategies to optimize Pola-V as a lymphoma therapeutic. Significance: These findings unravel the molecular basis of response heterogeneity to Pola-V and identify approaches that might be deployed therapeutically to enhance the efficacy of CD79B-specific tumor killing. In addition, they reveal a novel post-translational mechanism used by normal and malignant germinal center B cells to regulate expression of the BCR. See related commentary by Leveille, p. 1577 See related article by Meriranta et al.

4 May 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SSSebastian Scheich
Sebastian Scheich
JCJiji Chen
Jiji Chen
JLJiamin Liu
Jiamin Liu
Frank SchnütgenFrank Schnütgen
Frank Schnütgen
JEJulius C. Enssle
Julius C. Enssle
LSLouis M. Staudt
Louis M. Staudt
Diffuse large B-cell lymphoma (DLBCL) can be subdivided into the activated B-cell (ABC) and germinal center B cell–like (GCB) subtypes. Self-antigen engagement of B-cell receptors (BCR) in ABC tumors induces their clustering, thereby initiating chronic active signaling and activation of NF-κB and PI3 kinase. Constitutive BCR signaling is essential in some GCB tumors but primarily activates PI3 kinase. We devised genome-wide CRISPR–Cas9 screens to identify regulators of IRF4, a direct transcriptional target of NF-κB and an indicator of proximal BCR signaling in ABC DLBCL. Unexpectedly, inactivation of N-linked protein glycosylation by the oligosaccharyltransferase-B (OST-B) complex reduced IRF4 expression. OST-B inhibition of BCR glycosylation reduced BCR clustering and internalization while promoting its association with CD22, which attenuated PI3 kinase and NF-κB activation. By directly interfering with proximal BCR signaling, OST-B inactivation killed models of ABC and GCB DLBCL, supporting the development of selective OST-B inhibitors for the treatment of these aggressive cancers. Significance: DLBCL depends on constitutive BCR activation and signaling. There are currently no therapeutics that target the BCR directly and attenuate its pathologic signaling. Here, we unraveled a therapeutically exploitable, OST-B–dependent glycosylation pathway that drives BCR organization and proximal BCR signaling. This article is highlighted in the In This Issue feature, p. 1749

17 June 2026
Verified
Other
Open access
PDF file
SCSean R. Corcoran
Sean R. Corcoran
JPJames D. Phelan
James D. Phelan
JCJaewoo Choi
Jaewoo Choi
GSGalina Shevchenko
Galina Shevchenko
RFRachel E. Fenner
Rachel E. Fenner
LSLouis M. Staudt
Louis M. Staudt
CD79B is degraded in a lysosomal, not proteasomal manner

17 June 2026
Verified
Other
Open access
PDF file
SCSean R. Corcoran
Sean R. Corcoran
JPJames D. Phelan
James D. Phelan
JCJaewoo Choi
Jaewoo Choi
GSGalina Shevchenko
Galina Shevchenko
RFRachel E. Fenner
Rachel E. Fenner
LSLouis M. Staudt
Louis M. Staudt
KLHL6 loss does not score as a negative regulator of surface CD79B or Pola-V sensitivity in CRISPR screens of ABC DLBCL cell lines and KLHL6 loss does not sensitize to MMAE

17 June 2026
Verified
Other
Open access
SCSean R. Corcoran
Sean R. Corcoran
JPJames D. Phelan
James D. Phelan
JCJaewoo Choi
Jaewoo Choi
GSGalina Shevchenko
Galina Shevchenko
RFRachel E. Fenner
Rachel E. Fenner
LSLouis M. Staudt
Louis M. Staudt
CD79B Segregation Score and Pola-V CSS for Golgi glycosylation genes shows specific sugar regulators of surface CD79B and Pola-V sensitization